$VBIVQ
VBI Vaccines Inc/BC Stock $vbivq

$vbivq Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000149315224014744 Filed on April 16, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023
Revenue		$853.0K	$8.682M
YoY Change		191.13%	702.4%
Cost Of Revenue		$2.943M	$12.51M
YoY Change		-11.57%	10.92%
Gross Profit		-$2.090M	-$3.825M
YoY Change		-31.14%	-62.48%
Gross Profit Margin		-245.02%	-44.06%
Selling, General & Admin		$8.906M	$42.14M
YoY Change		-43.94%	-24.91%
% of Gross Profit
Research & Development		$1.368M	$9.343M
YoY Change		-45.67%	-39.75%
% of Gross Profit
Depreciation & Amortization		$470.0K	$1.990M
YoY Change		-9.62%	-3.44%
% of Gross Profit
Operating Expenses		$10.27M	$51.49M
YoY Change		-44.18%	-37.9%
Operating Profit		-$12.36M	-$55.31M
YoY Change		-42.33%	-32.4%
Interest Expense		$13.35M	-$12.93M
YoY Change		4380.2%	-422.56%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income		-$13.00K	-$92.84M
YoY Change		-99.94%	-18.06%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings		-$156.0K	-$93.84M
YoY Change		-99.26%	-17.18%
Net Earnings / Revenue		-18.29%	-1080.87%
Basic Earnings Per Share			-$6.03
Diluted Earnings Per Share		-$0.01	-$6.03
COMMON SHARES
Basic Shares Outstanding	28.43M shares	23.69M shares	15.57M shares
Diluted Shares Outstanding			15.57M shares

Balance Sheet

Concept	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$23.69M	$23.69M
YoY Change	-62.18%	-62.18%
Cash & Equivalents	$23.69M
Short-Term Investments
Other Short-Term Assets	$2.779M	$2.779M
YoY Change	-54.13%	-35.89%
Inventory	$8.499M	$8.499M
Prepaid Expenses	$2.284M
Receivables	$0.00	$0.00
Other Receivables	$1.268M	$1.268M
Total Short-Term Assets	$36.23M	$36.23M
YoY Change	-53.36%	-53.36%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.91M	$11.91M
YoY Change	-2.77%	-23.48%
Goodwill	$1.130M
YoY Change	-46.87%
Intangibles	$36.50M
YoY Change	-37.44%
Long-Term Investments
YoY Change
Other Assets	$1.178M	$1.178M
YoY Change	-13.06%	-13.06%
Total Long-Term Assets	$50.72M	$50.72M
YoY Change	-34.47%	-34.47%
TOTAL ASSETS
Total Short-Term Assets	$36.23M	$36.23M
Total Long-Term Assets	$50.72M	$50.72M
Total Assets	$86.95M	$86.95M
YoY Change	-43.93%	-43.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.431M	$6.431M
YoY Change	-50.43%	-50.43%
Accrued Expenses	$6.602M	$6.602M
YoY Change	-55.45%	-55.45%
Deferred Revenue	$7.276M
YoY Change	1678.97%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$50.77M	$50.77M
YoY Change
Total Short-Term Liabilities	$75.74M	$75.74M
YoY Change	105.01%	105.01%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Other Long-Term Liabilities	$3.688M	$3.688M
YoY Change	-27.59%	-27.59%
Total Long-Term Liabilities	$3.688M	$3.688M
YoY Change	-93.17%	-93.17%
TOTAL LIABILITIES
Total Short-Term Liabilities	$75.74M	$75.74M
Total Long-Term Liabilities	$3.688M	$3.688M
Total Liabilities	$79.42M	$79.42M
YoY Change	-12.65%	-12.65%
SHAREHOLDERS EQUITY
Retained Earnings	-$582.4M
YoY Change	18.96%
Common Stock	$561.6M
YoY Change	5.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$7.527M	$7.527M
YoY Change
Total Liabilities & Shareholders Equity	$86.95M	$86.95M
YoY Change	-43.93%	-43.93%

Cashflow Statement

Concept	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$156.0K	-$93.84M
YoY Change	-99.26%	-17.18%
Depreciation, Depletion And Amortization	$470.0K	$1.990M
YoY Change	-9.62%	-3.44%
Cash From Operating Activities	-$12.05M	-$60.88M
YoY Change	-36.72%	-17.39%
INVESTING ACTIVITIES
Capital Expenditures	$167.0K	$867.0K
YoY Change	-88.5%	-80.04%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$167.0K	-$867.0K
YoY Change	-88.5%	-80.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$24.27M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	268.0K	22.70M
YoY Change		16.71%
NET CHANGE
Cash From Operating Activities	-12.05M	-60.88M
Cash From Investing Activities	-167.0K	-867.0K
Cash From Financing Activities	268.0K	22.70M
Net Change In Cash	-11.95M	-39.05M
YoY Change	-41.69%	-33.88%
FREE CASH FLOW
Cash From Operating Activities	-$12.05M	-$60.88M
Capital Expenditures	$167.0K	$867.0K
Free Cash Flow	-$12.22M	-$61.75M
YoY Change	-40.38%	-20.87%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2022	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Registrant Name EntityRegistrantName	VBI Vaccines Inc/BC
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	A1
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	00-0000000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent		usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent		usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent		usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	VBIV	Deemed Dividend On Certain Warrants DeemedDividendOnCertainWarrants		usd
CY2023	VBIV	Warrants Issued In Connection With Financing Transactions Value WarrantsIssuedInConnectionWithFinancingTransactionsValue		usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2023	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt		usd
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts		usd
CY2023	VBIV	Non Cash Adjustments For Prior Periods From Adoption NonCashAdjustmentsForPriorPeriodsFromAdoption		usd
CY2022	VBIV	Warrants Issued In Connection With Financing Transactions WarrantsIssuedInConnectionWithFinancingTransactions		usd
CY2023	VBIV	Warrants Modification In Connection With Debt Amendment WarrantsModificationInConnectionWithDebtAmendment		usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent		usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent		usd
CY2022	VBIV	Contract With Customer Liability Amount Received ContractWithCustomerLiabilityAmountReceived		usd
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized		usd
CY2022	VBIV	Contract With Customer Liability Currency Translation ContractWithCustomerLiabilityCurrencyTranslation		usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-37769
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	160 Second Street
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Floor 3
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02142
CY2023	dei	City Area Code CityAreaCode	(617)
CY2023	dei	Local Phone Number LocalPhoneNumber	830-3031
CY2023	dei	Security12b Title Security12bTitle	Common Shares, no par value per share
CY2023	dei	Trading Symbol TradingSymbol	VBIV
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	21950347	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28432275	shares
CY2023	dei	Auditor Firm AuditorFirmId	274
CY2023	dei	Auditor Name AuditorName	EISNERAMPER LLP
CY2023	dei	Auditor Location AuditorLocation	Iselin, New Jersey
CY2023Q4	us-gaap	Cash Cash	23685000	usd
CY2022Q4	us-gaap	Cash Cash	62629000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	94000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	8499000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	6599000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2284000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2309000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1763000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	6059000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	36231000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	77690000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1178000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1355000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9665000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12253000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2248000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3316000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	36499000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	58345000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	1130000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	2127000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	50720000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	77396000	usd
CY2023Q4	us-gaap	Assets Assets	86951000	usd
CY2022Q4	us-gaap	Assets Assets	155086000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6431000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12973000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	10284000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	22588000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7276000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	409000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	976000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	972000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	50769000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	75736000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	36942000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1832000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2204000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1295000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2365000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	48888000	usd
CY2023Q4	us-gaap	Accrued Participation Liabilities Due In Next Operating Cycle AccruedParticipationLiabilitiesDueInNextOperatingCycle	561000	usd
CY2022Q4	us-gaap	Accrued Participation Liabilities Due In Next Operating Cycle AccruedParticipationLiabilitiesDueInNextOperatingCycle	524000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3688000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	53981000	usd
CY2023Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2022Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23918983	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23918983	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8608539	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8608539	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	454214000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	442312000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	107431000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	90020000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	28327000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	21440000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-582445000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-489609000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	7527000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	64163000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	86951000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	155086000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8682000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1082000	usd
CY2023	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	12507000	usd
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	11276000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9343000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15506000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	42143000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	56120000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	24600000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	88593000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	82902000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-79911000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-81820000	usd
CY2023	us-gaap	Interest Expense InterestExpense	6401000	usd
CY2022	us-gaap	Interest Expense InterestExpense	4007000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-6524000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-27476000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-92836000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-113303000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-92836000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-113303000	usd
CY2023	VBIV	Deemed Dividend On Certain Warrants DeemedDividendOnCertainWarrants	1005000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-93841000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-113303000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	6887000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	23005000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-85949000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-90298000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.03
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.03
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-13.16
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15572494	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15572494	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8608530	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	143882000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	-681000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	12000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1550000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	9698000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-113303000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	23005000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	64163000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	22652000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	6661000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-92836000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	6887000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	7527000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-92836000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-113303000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1990000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2061000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	6661000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	9698000	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1881000	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1707000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-172000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	24600000	usd
CY2023	VBIV	Inventory Reserve InventoryReserve	1668000	usd
CY2022	VBIV	Inventory Reserve InventoryReserve	1186000	usd
CY2023	VBIV	Increase Decrease In Operating Right Of Use Assets IncreaseDecreaseInOperatingRightOfUseAssets	-1408000	usd
CY2022	VBIV	Increase Decrease In Operating Right Of Use Assets IncreaseDecreaseInOperatingRightOfUseAssets	-1357000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-6609000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-27445000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-99000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	87000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3718000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5690000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-17000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-18000	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-4281000	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	2738000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-102000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	173000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-6652000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	8893000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	6356000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	16000	usd
CY2023	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-11943000	usd
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-2910000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1406000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1347000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-60883000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-73695000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	867000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4344000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-867000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4344000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	24273000	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1575000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	12000	usd
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	20000000	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	563000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	22698000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19449000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	108000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-475000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-38944000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-59065000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	62629000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	121694000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	23685000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	62629000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	6130000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	3231000	usd
CY2022	VBIV	Non Cash Adjustments For Prior Periods From Adoption NonCashAdjustmentsForPriorPeriodsFromAdoption	681000	usd
CY2023	VBIV	Warrants Issued In Connection With Financing Transactions WarrantsIssuedInConnectionWithFinancingTransactions	10760000	usd
CY2022	VBIV	Warrants Modification In Connection With Debt Amendment WarrantsModificationInConnectionWithDebtAmendment	1550000	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	142000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	406000	usd
CY2023	VBIV	Share Issuance Costs Included In Accounts Payable And Other Current Liabilities ShareIssuanceCostsIncludedInAccountsPayableAndOtherCurrentLiabilities	112000	usd
CY2022	VBIV	Share Issuance Costs Included In Accounts Payable And Other Current Liabilities ShareIssuanceCostsIncludedInAccountsPayableAndOtherCurrentLiabilities	67000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80C_eus-gaap--NatureOfOperations_zgdPvp3igMMi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. <span id="xdx_82B_zvxUU0rZYnA8">NATURE OF BUSINESS AND CONTINUATION OF BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate Overview</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VBI Vaccines Inc. (the “Company” or “VBI”) was incorporated under the laws of British Columbia, Canada on April 9, 1965.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and its wholly-owned subsidiaries, VBI Vaccines (Delaware) Inc., a Delaware corporation (“VBI DE”); VBI DE’s wholly-owned subsidiary, Variation Biotechnologies (US), Inc., a Delaware corporation (“VBI US”); Variation Biotechnologies, Inc. a Canadian company and the wholly-owned subsidiary of VBI US (“VBI Cda”); SciVac Ltd. an Israeli company (“SciVac”); SciVac Hong Kong Limited (“SciVac HK”) and VBI Vaccines B.V a Netherlands company (“VBI BV”), are collectively referred to as the “Company”, “we”, “us”, “our”, or “VBI”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s registered office is located at Suite 1700, Park Place, 666 Burrard Street, Vancouver, BC V6C 2X8 with its principal office located at 160 Second Street, Floor 3, Cambridge, MA 02142. In addition, the Company has manufacturing facilities located in Rehovot, Israel and research facilities located in Ottawa, Ontario, Canada.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal Operations</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VBI is a commercial-stage biopharmaceutical company driven by immunology in the pursuit of prevention and treatment of disease. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP (“eVLP”) platform technology and a proprietary mRNA-launched eVLP (“MLE”) platform technology, VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B (“HBV”), COVID-19 and coronaviruses, and cytomegalovirus (“CMV”), as well as aggressive cancers including glioblastoma (“GBM”). VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2023 Organizational Changes</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As announced on April 4, 2023, the Company reduced its internal workforce by <span id="xdx_907_ecustom--OperatingExpensesAndWorkforceReductionPercentage_dp_uPure_c20230404__20230404__srt--RangeAxis__srt--MinimumMember_zevO2Y3kw93a" title="Operating expenses and workforce reduction percentage">30</span>-<span id="xdx_900_ecustom--OperatingExpensesAndWorkforceReductionPercentage_dp_uPure_c20230404__20230404__srt--RangeAxis__srt--MaximumMember_z6a9bXHMPeG5" title="Operating expenses and workforce reduction percentage">35</span>%, which began in April and was completed by the end of September 2023. As a result of this and other reductions in spend, VBI operating expenses, excluding impairment charges, were <span id="xdx_90C_ecustom--OperatingExpensesAndWorkforceReductionPercentage_dp_uPure_c20230401__20230630__srt--RangeAxis__srt--MinimumMember_zU8htzKHvhE8" title="Operating expenses and workforce reduction percentage">30</span>-<span id="xdx_901_ecustom--OperatingExpensesAndWorkforceReductionPercentage_dp_uPure_c20230401__20230630__srt--RangeAxis__srt--MaximumMember_zuE2wPqGtV5b" title="Operating expenses and workforce reduction percentage">35</span>% lower in the second half of 2023 as compared with the second half of 2022<i>.</i> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity and Going Concern</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company faces a number of risks, including but not limited to, uncertainties regarding the success of the development and commercialization of its products, demand and market acceptance of the Company’s products, and reliance on major customers. The Company anticipates that it will continue to incur significant operating costs and losses in connection with the development and commercialization of its products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has an accumulated deficit of $<span id="xdx_900_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20231231_zS8vimrCcaV2">582,445</span> and cash of $<span id="xdx_909_eus-gaap--Cash_iI_pn3n3_c20231231_zWglfNBSq9p9">23,685</span> as of December 31, 2023. Cash outflows from operating activities were $<span id="xdx_903_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20230101__20231231_zadG4GJh4oPj">60,883</span> for the year-ended December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company will require significant additional funds to conduct clinical and non-clinical trials, achieve and maintain regulatory approvals, and commercially launch and sell our approved products. Additional financing may be obtained from the issuance of equity securities, the issuance of additional debt, government or non-governmental organization grants or subsidies, and/or revenues from potential business development transactions, if any. There is no assurance the Company will manage to obtain these sources of financing, if required. Based on available cash at December 31, 2023, together with the net proceeds from the April 2024 Offering, in order to continue to fund our operations, we must raise additional equity or debt capital in the near term and cannot provide any assurance that we will be successful in doing so. If we are unable to obtain additional financing in the near future, we may be required to pursue a reorganization proceeding, including under applicable bankruptcy or insolvency laws. The above conditions raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 9, 2021, the Company and the Coalition for Epidemic Preparedness Innovations (“CEPI”) announced a partnership (“CEPI Funding Agreement”) to develop eVLP vaccine candidates against SARS-COV-2 variants, including the Beta variant, also known as the B.1.351 variant and 501Y.V2, first identified in South Africa. CEPI agreed to provide up to $<span id="xdx_90D_ecustom--MaximumDeferredFundAgreed_iI_pn3n3_c20210309__us-gaap--TypeOfArrangementAxis__custom--CEPIFundingAgreementMember_zqsFWPRMJJE4" title="Maximum deferred fund agreed">33,018</span> to support the advancement of VBI-2905, a monovalent eVLP candidate expressing the pre-fusion form of the spike protein from the Beta variant, through Phase I clinical development. This funding will also support preclinical expansion of additional multivalent vaccine candidates designed to evaluate the potential breadth of our eVLP technology. The preclinical expansion is intended to develop clinic-ready vaccine candidates capable of addressing emerging variants. See more information on the CEPI Funding Agreement in Note 15.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 26, 2022, we 1) filed a registration statement on Form S-3 (File No. 333-267109), which included a base prospectus which covers the offering, issuance and sale of up to $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn3n3_c20220825__20220826__srt--RangeAxis__srt--MaximumMember_zjhaykPVOoIg" title="Issuance and sale of common shares">300,000</span> of common shares, warrants, units and/or subscription rights; and 2) entered into an Open Market Sale Agreement with Jefferies LLC (“Jefferies”), pursuant to which we may offer and sell our common shares having an aggregate price of up to $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn3n3_c20220825__20220826__us-gaap--TypeOfArrangementAxis__custom--ATMProgramMember__srt--RangeAxis__srt--MaximumMember_zh26pWJQMt5b" title="Share value remaining, available for sale">125,000</span> from time to time through Jefferies, acting as agent or principal (the “ATM Program”). During the year ended December 31, 2023, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ATMProgramMember_zsx3HS94zs9a" title="Shares issued during period, shares">1,046,808</span> common shares under the ATM Program, for total gross proceeds of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20220826__20220826__us-gaap--TypeOfArrangementAxis__custom--ATMProgramMember_zNbCusUot4Ob" title="Proceeds from issuance of equity">738</span> at a weighted average price of $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220826__us-gaap--TypeOfArrangementAxis__custom--ATMProgramMember_zKGI04LWESs6" title="Average price per share">0.7048</span> per share. The Company incurred $<span id="xdx_905_eus-gaap--PaymentsOfStockIssuanceCosts_pn3n3_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ATMProgramMember_zCjPEFn2zkrc" title="Stock issuance costs">107</span> in sales agent commissions and share issuance costs related to the common shares issued during the year ended December 31, 2023, resulting in net proceeds of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3n3_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ATMProgramMember_zaxATtr3Y40j" title="Net proceeds">631</span>. As of December 31, 2023, approximately $<span id="xdx_905_ecustom--RemainingShareValueAvailableForIssuance_iI_pn3n3_c20231231__us-gaap--TypeOfArrangementAxis__custom--ATMProgramMember_zEduYwVHbswe" title="Share value remaining, available for sale">124,262</span> of common shares remained available for issuance under the ATM Program.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Upon filing of this Form 10-K, we will become subject to General Instruction I.B.6 of Form S-3, pursuant to which in no event will we sell our common shares in a registered primary offering using Form S-3 with a value exceeding more than one-third of our public float in any 12 calendar month period so long as our public float remains below $<span id="xdx_908_ecustom--PublicFloatValue_iI_pn3n3_c20240416__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zddULKyFOnI" title="Public float value">75,000</span>. Therefore, the amount we may be able to raise using the ATM Program will be significantly less than $<span id="xdx_902_ecustom--PublicFloatValue_iI_pn3n3_c20240416__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ATMProgramMember__srt--RangeAxis__srt--MinimumMember_z9TWbbgYS3si" title="Public float value">125,000</span>, until such time as our public float held by non-affiliates exceeds $<span id="xdx_907_ecustom--PublicFloatValue_iI_pn3n3_c20240416__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--NonAffiliatesMember_zhH4lQQBa9v1" title="Public float value">75,000</span>. The aggregate market value of our outstanding common shares held by non-affiliates as of filing of this Form 10-K, or the public float, is approximately $<span id="xdx_908_ecustom--PublicFloatValue_iI_pn3n3_c20240416__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--NonAffiliatesMember__srt--StatementScenarioAxis__custom--CalculatedBasedOnCommonSharesMember_zNBbdC5strji" title="Public float value">25,174</span>, which was calculated based on <span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240416__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--NonAffiliatesMember__srt--StatementScenarioAxis__custom--CalculatedBasedOnCommonSharesMember_zTh3V17fWruh" title="Common shares outstanding">27,334,007</span> common shares outstanding held by non-affiliates and at a price of $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240416__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--NonAffiliatesMember__srt--StatementScenarioAxis__custom--CalculatedBasedOnCommonSharesMember_zgHIHgsOKeBk" title="Share price per share">0.9210</span> per share, the closing price of our common shares on April 8, 2024. As of the date hereof, we have not offered or sold any securities pursuant to General Instruction I.B.6 of Form S-3 during the prior 12 calendar month period that ends on and includes the date hereof.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September 2022, the Company refinanced its existing term loan facility with K2HV to increase the amount of term loans available to $<span id="xdx_90B_ecustom--IncreaseInAmountOfTermLoansAvailable_iI_pn3n3_c20220930__dei--LegalEntityAxis__custom--K2HealthventuresLLCMember_zwcWrqwamfHg" title="Increase amount of term loans available">100,000</span> among other items. See Note 11 for more details. The refinanced long-term debt has a maturity date of September 14, 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 5, 2023, the Company announced the expansion of its hepatitis B partnership with Brii Bio. Through (i) a Collaboration and License Agreement (the “Collaboration Agreement”), dated July 5, 2023, by and between the Company and Brii Bio, and (ii) the Amended and Restated Collaboration and License Agreement (the “A&R Collaboration Agreement, which amended and restated the Brii Collaboration and License Agreement, and together with the Collaboration Agreement, the “Brii Collaboration Agreements”), dated July 5, 2023, by and between the Company and Brii Bio, Brii Bio expanded its exclusive license to VBI-2601 to global rights and acquired an exclusive license for PreHevbri in Asia Pacific (“APAC”), excluding Japan. As part of this collaboration, Brii Bio paid the Company an upfront payment of $<span id="xdx_908_ecustom--UpfrontPayment_pn3n3_c20230705__20230705_z8nGQLXLXlR9" title="Upfront payment">15,000</span> consisting of a $<span id="xdx_902_eus-gaap--EquityMethodInvestmentAggregateCost_iI_pn3n3_c20230705_zO3qRQW1Y4a" title="Equity investment">3,000</span> equity investment in a concurrent registered direct offering (discussed below), $<span id="xdx_90D_ecustom--PaymentClinicalAndCommercialManufacture_iI_pn3n3_c20230705_zTMtdtEmzEQ7" title="Payment for clinical and commercial manufacture">5,000</span> as an advance payment for the clinical and commercial manufacture and supply of VBI-2601 and PreHevbri and any related manufacturing expenditures pursuant to a supply agreement (the “Supply Agreement”) dated July 5, 2023, by and between the Company and Brii Bio, and $<span id="xdx_903_ecustom--NonrefundableUpfrontPayment_iI_pn3n3_c20230705_zOWXnOp3vsve" title="Non-refundable upfront payment">7,000</span> as a non-refundable upfront payment pursuant to the Brii Collaboration Agreements. In addition, pursuant to the Letter Agreement (the “Letter Agreement”), dated July 5, 2023, by and among the Company, SciVac, and Brii Bio, the Company also granted to Brii Bio a security interest, subject to a Subordination Agreement between Brii Bio and K2 HealthVentures LLC (“K2HV”), in all of its respective right, title, and interest in and to all intellectual property, know-how, and licenses to the extent related to PreHevbri and VBI-2601, and all proceeds of the foregoing, in order to secure performance of all of the Company’s obligations under the Brii Collaboration Agreements, the Supply Agreement, and the Loan Agreement (as defined herein).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2023, the Company closed (i) an underwritten public offering of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230701__20230731__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_zLRwTW93mNCd" title="Common shares, issued">12,445,454</span> common shares and accompanying common warrants to purchase up to <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20230731__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_zPz5OyTUj8bb" title="Purchase of warrants">12,545,454</span> common shares (which included <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230701__20230731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_ziRbqR1MSY15" title="Common shares, issued">1,536,363</span> common shares and common warrants to purchase up to <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_zwFna3wf9Zo3" title="Purchase of warrants">1,636,363</span> common shares issued pursuant to the underwriters’ partial exercise of their option to purchase additional common shares and common warrants) at a combined public offering price of $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_c20230731__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_zpSHRDRjQkH9" title="Shares issued, price">1.65</span> per common share and accompanying common warrant, and (ii) a concurrent registered direct offering, pursuant to the expanded hepatitis B partnership with Brii Bio, of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230701__20230731__us-gaap--SubsidiarySaleOfStockAxis__custom--DirectOfferingMember_znBGEr2LCYy7" title="Common shares, issued">1,818,182</span> common shares and accompanying common warrants to purchase up to <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20230731__us-gaap--SubsidiarySaleOfStockAxis__custom--DirectOfferingMember_zx1UofKDL95c" title="Purchase of warrants">1,818,182</span> common shares, at a combined purchase price of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20230731__us-gaap--SubsidiarySaleOfStockAxis__custom--DirectOfferingMember_zDdFrCSVxlAg" title="Shares issued, price">1.65</span> per share and accompanying common warrant. The accompanying common warrants issued and sold in each of the underwritten public offering and the registered direct offering have an initial exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230731__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_zoYTgmMch3A8" title="Warrant exercise price"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230731__us-gaap--SubsidiarySaleOfStockAxis__custom--DirectOfferingMember_z7G2n9mWfm6c" title="Warrant exercise price">1.65</span></span> per share, which, pursuant to certain anti-dilution provisions of the warrants, was reduced to $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--RangeAxis__srt--MinimumMember_z1sDmjoC1OR8" title="Warrant price">0.6057</span> per share, as of December 31, 2023, and expire five years from the date of issuance. The aggregate gross proceeds from the underwritten public offering, including aggregate gross proceeds from the underwriters’ exercise of their option to purchase additional securities, were $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn3n3_c20230701__20230731__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_zE20Dd8TB8P9" title="Gross proceeds">20,500</span>. The aggregate gross proceeds from the concurrent registered direct offering were $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn3n3_c20230701__20230731__us-gaap--SubsidiarySaleOfStockAxis__custom--DirectOfferingMember_zTI6ov1ceLD3" title="Gross proceeds">3,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, the Company had outstanding warrants to purchase up to an aggregate of <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdFnUjZZyl2i" title="Warrants to purchase common stock">14,363,636</span> common shares, issued in July 2023. Pursuant to certain anti-dilution provisions of the warrants, as the consideration paid per common share under the ATM Program was less than the exercise price of such warrants in effect immediately prior to such issuance (“New Issuance Price”), the exercise price of the warrants (the “Exercise Price”) was reduced to the New Issuance Price. As of December 31, 2023, the Exercise Price in effect was $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrPgViUJfiWl" title="Warrant price">0.6057</span> per share, which resulted in a deemed dividend of $<span id="xdx_90E_ecustom--DeemedDividendOnCertainWarrants_pn3n3_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJWks1qKlhA3" title="Deemed dividend">1,005</span> as the fair value of the warrants was greater subsequent to the reduction in Exercise Price than it was immediately prior to such reduction in Exercise Price. The fair values were determined using the Black-Scholes option pricing model.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 1, 2023, the Company received a letter from the Listing Qualifications Department of the Nasdaq Capital Market’s (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common shares for the 30 consecutive business day period between September 19, 2023 through October 31, 2023, it did not meet the minimum bid price of $1.00 per share required for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company will be provided with a compliance period of 180 calendar days, or until April 29, 2024 (the “Compliance Period”), in which to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(A).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In order to regain compliance with Nasdaq’s minimum bid price requirement, the common shares must maintain a minimum closing bid price of $1.00 for a minimum of ten consecutive business days during the Compliance Period. In the event that the Company does not regain compliance by the end of the Compliance Period, it may be eligible for additional time to regain compliance. To qualify, the Company will be required to meet the continued listing requirement for the market value of our publicly held shares and all other initial listing standards for Nasdaq, with the exception of the bid price requirement, and will need to provide written notice of our intention to cure the deficiency during the second compliance period, by effecting a reverse stock split if necessary. If we meet these requirements, the Company may be granted an additional 180 calendar days to regain compliance. The Company has not regained compliance as of the date of this Form 10-K, and if it fails to regain compliance during the Compliance Period or any subsequent grace period granted by Nasdaq, its common shares will be subject to delisting by Nasdaq, which could seriously decrease or eliminate the value of an investment in the common shares and result in significantly increased uncertainty as to the Company’s ability to raise additional capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-582445000	usd
CY2023Q4	us-gaap	Cash Cash	23685000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-60883000	usd
CY2023Q3	VBIV	Upfront Payment UpfrontPayment	15000000	usd
CY2023Q3	us-gaap	Equity Method Investment Aggregate Cost EquityMethodInvestmentAggregateCost	3000000	usd
CY2023Q3	VBIV	Payment Clinical And Commercial Manufacture PaymentClinicalAndCommercialManufacture	5000000	usd
CY2023Q3	VBIV	Nonrefundable Upfront Payment NonrefundableUpfrontPayment	7000000	usd
CY2023Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-30 reverse stock split
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_845_eus-gaap--UseOfEstimates_zTZ0DNH9o2T7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zpBHPVlvfEUe">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual amounts could differ from the estimates made. We continually evaluate estimates used in the preparation of the consolidated financial statements for reasonableness. Appropriate adjustments, if any, to the estimates used are made prospectively based upon such periodic evaluation. The significant areas of estimation include revenue recognition, determining the deferred tax valuation allowance, estimating accrued research and development expenses, the inputs in determining the fair value of the in-process research and development (“IPR&D”) and goodwill as part of the impairment analysis and the inputs in determining the fair value of equity-based awards and warrants issued. Actual results may differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_zPRTp0Sqi16e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zFcSaeZQRWy6">Concentration of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash and accounts receivable. We place our cash primarily in commercial checking accounts. Commercial bank balances may from time to time exceed federal insurance limits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has not experienced any losses in cash and accounts receivable for the years ended December 31, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	VBIV	Schedule Of Estimated Useful Lives Of Property And Equipment ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipment	<p id="xdx_89B_ecustom--ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipment_zs2wZ0n2j6zf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The assets are depreciated by the straight-line method over the estimated useful lives of the related assets as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_z4PpuweiM2j1" style="display: none">SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and office equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zEK3ctAe9sb6" title="Property, Plant and Equipment, Useful Life">5</span>-<span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zkJxWrh0K9Vd" title="Property, Plant and Equipment, Useful Life">14</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery and equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zOieHQA7l2C6" title="Property, Plant and Equipment, Useful Life">3</span>-<span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zShbqPXm7CSk" title="Property, Plant and Equipment, Useful Life">7</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zzijjN4XZpde" title="Property, plant and equipment, useful life">2</span>-<span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zbIcJkI8513c" title="Property, plant and equipment, useful life">3</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zg5NkhCtwaUl" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2023%23UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"><span style="-sec-ix-hidden: xdx2ixbrl0577">shorter of useful life or the term of the lease</span></span></span></td></tr> </table>
CY2023Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	48077000	usd
CY2022Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	56510000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1661000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	893000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	2734000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1869000	usd
CY2023Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	4104000	usd
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	3837000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	8499000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	6599000	usd
CY2023	VBIV	Inventory Reserve InventoryReserve	1668000	usd
CY2022	VBIV	Inventory Reserve InventoryReserve	1186000	usd
CY2023Q4	us-gaap	Government Contract Receivable GovernmentContractReceivable	1268000	usd
CY2022Q4	us-gaap	Government Contract Receivable GovernmentContractReceivable	4033000	usd
CY2023Q4	VBIV	Other Current Assets OtherCurrentAssets	495000	usd
CY2022Q4	VBIV	Other Current Assets OtherCurrentAssets	2026000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1763000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	6059000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	24600000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	20052000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10387000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9665000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	20234000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7981000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12253000	usd
CY2023	us-gaap	Depreciation Depreciation	1990000	usd
CY2022	us-gaap	Depreciation Depreciation	2009000	usd
CY2023Q2	VBIV	Estimated Fair Value Of Assets Discount Rate EstimatedFairValueOfAssetsDiscountRate	0.15	pure
CY2023	us-gaap	Finite Lived Intangible Assets Foreign Currency Translation Gain Loss FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss	754000	usd
CY2022	us-gaap	Finite Lived Intangible Assets Foreign Currency Translation Gain Loss FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss	3690000	usd
CY2023Q4	us-gaap	Goodwill Gross GoodwillGross	8714000	usd
CY2023Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	7292000	usd
CY2023Q4	VBIV	Goodwill Cumulative Currency Translation GoodwillCumulativeCurrencyTranslation	-292000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	1130000	usd
CY2022Q4	us-gaap	Goodwill Gross GoodwillGross	8714000	usd
CY2022Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	6292000	usd
CY2022Q4	VBIV	Goodwill Cumulative Currency Translation GoodwillCumulativeCurrencyTranslation	-295000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	2127000	usd
CY2023Q4	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	1000000	usd
CY2023	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	3000	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	1000000	usd
CY2022	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	134000	usd
CY2023Q4	VBIV	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	2018000	usd
CY2022Q4	VBIV	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	6561000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1674000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3250000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1934000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4036000	usd
CY2023Q4	us-gaap	Deferred Credits And Other Liabilities Current DeferredCreditsAndOtherLiabilitiesCurrent	3601000	usd
CY2022Q4	us-gaap	Deferred Credits And Other Liabilities Current DeferredCreditsAndOtherLiabilitiesCurrent	6966000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1057000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1775000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	10284000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	22588000	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16323250	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1085526	shares
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	50769000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	48888000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	50769000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	48888000	usd
CY2023	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	55699000	usd
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	6183000	usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	3515000	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1881000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1707000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-172000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	1663000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	1387000	usd
CY2023	us-gaap	Interest Expense InterestExpense	6401000	usd
CY2022	us-gaap	Interest Expense InterestExpense	4007000	usd
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	393000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	442000	usd
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.0833	pure
CY2023	us-gaap	Severance Costs1 SeveranceCosts1	106000	usd
CY2022	us-gaap	Severance Costs1 SeveranceCosts1	5000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1650288	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	30.53
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	1650288	shares
CY2023	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P8Y2M1D
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	718513	shares
CY2023Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	63.81
CY2023	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P6Y6M
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P6Y6M14D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023Q4	VBIV	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Vested ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueVested	0	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.1244	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9323	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0417	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0175	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y8M26D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M29D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.65
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	33.90
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	6661000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	9698000	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	2684000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y6M7D
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8682000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1082000	usd
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	9108000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2803000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2613000	usd
CY2023	VBIV	Contract With Customer Liability Amount Received ContractWithCustomerLiabilityAmountReceived	8056000	usd
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	1952000	usd
CY2023	VBIV	Contract With Customer Liability Currency Translation ContractWithCustomerLiabilityCurrencyTranslation	-391000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	9108000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7276000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1832000	usd
CY2023	VBIV	Description Of Vaccine Development DescriptionOfVaccineDevelopment	On March 9, 2021, the Company and CEPI announced the CEPI Funding Agreement, to develop eVLP vaccine candidates against SARS-COV-2 variants, including the Beta variant, also known as the B.1.351 variant and as 501Y.V2, first identified in South Africa. CEPI agreed to provide up to $33,018 to support the advancement of VBI-2905, a monovalent eVLP candidate expressing the pre-fusion form of the spike protein from the Beta variant strain, through Phase I clinical development
CY2020Q3	VBIV	Contribution Agreement Description ContributionAgreementDescription	75% of VBI Cda’s costs incurred in respect of the Project, subject to certain eligibility limitations as set forth in the Contribution Agreement and (ii) CAD $55,976 from the SIF to support the development of our coronavirus vaccine program, VBI-2900, though Phase II clinical studies (the “Project”)
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-92836000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-113303000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-92836000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-113303000	usd
CY2023	VBIV	Income Tax Reconciliation Expected Benefit Of Income Tax IncomeTaxReconciliationExpectedBenefitOfIncomeTax	-24602000	usd
CY2022	VBIV	Income Tax Reconciliation Expected Benefit Of Income Tax IncomeTaxReconciliationExpectedBenefitOfIncomeTax	-30025000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-319000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-386000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	203000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	1970000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	17707000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	12562000	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	2042000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	2771000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1628000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	2362000	usd
CY2023	VBIV	Income Tax Reconciliation Of Foreign Exchange On Unrecognized Temporary Differences IncomeTaxReconciliationOfForeignExchangeOnUnrecognizedTemporaryDifferences	2643000	usd
CY2022	VBIV	Income Tax Reconciliation Of Foreign Exchange On Unrecognized Temporary Differences IncomeTaxReconciliationOfForeignExchangeOnUnrecognizedTemporaryDifferences	10814000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	265000	usd
CY2023	VBIV	Income Tax Reconciliation Repatriation Of Foreign Earning IncomeTaxReconciliationRepatriationOfForeignEarning	141000	usd
CY2022	VBIV	Income Tax Reconciliation Repatriation Of Foreign Earning IncomeTaxReconciliationRepatriationOfForeignEarning	-308000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	292000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	240000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	108574000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	98147000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	14655000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	13995000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	830000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1072000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	2928000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	2253000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	-9672000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	-15461000	usd
CY2023Q4	VBIV	Allowable Capital Losses AllowableCapitalLosses	342000	usd
CY2022Q4	VBIV	Allowable Capital Losses AllowableCapitalLosses	56000	usd
CY2023Q4	VBIV	Deferred Tax Assets Debt Obligation DeferredTaxAssetsDebtObligation	-1902000	usd
CY2022Q4	VBIV	Deferred Tax Assets Debt Obligation DeferredTaxAssetsDebtObligation	-2683000	usd
CY2023Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	962000	usd
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	1201000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	116717000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	98580000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	116717000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	98580000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	454508000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	1866000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1865000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.13	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y4M9D
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1177000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	686000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	593000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	163000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2619000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	348000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2271000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	976000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1295000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8682000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1082000	usd
CY2023Q4	VBIV	Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	11913000	usd
CY2022Q4	VBIV	Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	15569000	usd

Files In Submission

Name	View Source	Status
0001493152-24-014744-index-headers.html	Edgar Link	pending
0001493152-24-014744-index.html	Edgar Link	pending
0001493152-24-014744.txt	Edgar Link	pending
0001493152-24-014744-xbrl.zip	Edgar Link	pending
ex10-62.htm	Edgar Link	pending
ex10-63.htm	Edgar Link	pending
ex10-64.htm	Edgar Link	pending
ex10-65.htm	Edgar Link	pending
ex10-66.htm	Edgar Link	pending
ex10-67.htm	Edgar Link	pending
ex10-68.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex97-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
form10-k_htm.xml	Edgar Link	completed
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vbiv-20231231.xsd	Edgar Link	pending
vbiv-20231231_def.xml	Edgar Link	unprocessable
vbiv-20231231_lab.xml	Edgar Link	unprocessable
vbiv-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
vbiv-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VBIVQ
VBI Vaccines Inc/BC Stock $vbivq

2024 Q2 Form 10-K Financial Statement

#000149315224014744 Filed on April 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VBIVQ VBI Vaccines Inc/BC Stock $vbivq

2024 Q2 Form 10-K Financial Statement

#000149315224014744 Filed on April 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VBIVQ
VBI Vaccines Inc/BC Stock $vbivq